安濟盛生物(wu)醫(yi)藥(yao)技術(廣州)有限公(gong)司(si)成立(li)于2018年6月,是一(yi)家專注(zhu)于骨(gu)骼、肌肉和(he)(he)關節疾病全新藥(yao)物(wu)研(yan)發的創業(ye)企(qi)(qi)業(ye)。公(gong)司(si)主要(yao)創始(shi)人(ren)曾于多(duo)家國際(ji)知名(ming)(ming)藥(yao)企(qi)(qi)擔任藥(yao)物(wu)研(yan)發和(he)(he)重(zhong)(zhong)(zhong)要(yao)管理職務,核心成員(yuan)在過(guo)去二十多(duo)年中曾帶領不同公(gong)司(si)團隊(dui)為(wei)多(duo)個(ge)重(zhong)(zhong)(zhong)要(yao)骨(gu)疾病上(shang)市藥(yao)物(wu)的研(yan)究(jiu)和(he)(he)臨床(chuang)開發作出重(zhong)(zhong)(zhong)大貢(gong)獻,包(bao)括denosumab (商(shang)品名(ming)(ming):Prolia和(he)(he)Xgeva)、romosozumab (商(shang)品名(ming)(ming):Evenity)、 拉(la)索(suo)昔芬lasofoxifene(商(shang)品名(ming)(ming):Fablyn)、Raloxifene (商(shang)品名(ming)(ming):Evista) 以及Teriparatide (商(shang)品名(ming)(ming):Forteo) 。